Are Pfizer's Growth Prospects in Trouble With Its Shocking Ibrance Setback?
The big drugmaker announced disappointing news on Monday from its Pallas late-stage study evaluating Ibrance as adjuvant therapy in treating early-stage breast cancer. This was a big blow to Pfizer. In the company's Q1 conference call in late April, chief scientific officer Mikael Dolsten said that "we feel very optimistic and good" about the Ibrance-as-adjuvant study.